Fixed-dose combination antituberculosis therapy as a risk factor for tuberculosis recurrence: an evidence-based case report

Fixed-dose combination antituberculosis therapy as a risk factor for tuberculosis recurrence: an evidence-based case report

Background: a patient with a history of tuberculosis (TB) has a risk up to 27% to develop recurrence within 2 years after being cured. Indonesia itself has more than 7,500 recurrent cases annually, regardless of reinfection or relapse. This is an important problem, as recurrent TB is associated with...

Descripció completa

Dades bibliogràfiques
Autors principals:	Arvin Pramudita, Cleopas M Rumende, Ardi Findyartini
Format:	Article
Idioma:	English
Publicat:	Interna Publishing 2017-04-01
Col·lecció:	Acta Medica Indonesiana
Matèries:	tuberculosis fixed-dose combination recurrent
Accés en línia:	http://www.actamedindones.org/index.php/ijim/article/view/327

Ítems similars

Treating more with less: Effectiveness and event outcomes of antituberculosis fixed-dose combination drug versus separate-drug formulation (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide) for pulmonary tuberculosis patients in real-world clinical practice
per: Jacqueline Mui Lan Lai, et al.
Publicat: (2019-01-01)

Relative Bioavailability of Rifampicin in Four Chinese Fixed-dose Combinations Compared with Rifampicin in Free Combinations
per: Hui Zhu, et al.
Publicat: (2015-01-01)

Comparison of the safety and efficacy of a fixed-dose combination regimen and separate formulations for pulmonary tuberculosis treatment
per: Jiun-Ting Wu, et al.
Publicat: (2015-06-01)

In vitro antimicrobial efficacy of a fixed-dose combination of RHZE against M. tuberculosis
per: Vanessa Albertina Agertt, et al.

Potential side effects of medicine on patients with tuberculosis fixed-dose combination in dr. Pirngadi Hospital, Medan
per: EVA SARTIKA DASOPANG, et al.
Publicat: (2020-02-01)

Comparison of sputum conversion time in tuberculosis treatment with fix-dose combination drugs and separate drug regimens
per: Soheila Khodakarim, et al.
Publicat: (2020-01-01)

Treatment outcome in smear-positive pulmonary tuberculosis patients treated with a fixed-dose drug combination regimen in comparison with a separate regimen: a randomized clinical trial
per: Seyed Saeed Hashemi Nazari, et al.
Publicat: (2021-01-01)

Experience of Fixed-Dose Combinations of Anti-Tuberculosis Drugs for Preventive Treatment in Children
per: O. D. Baronova, et al.
Publicat: (2023-12-01)

Optimization of Hypertension Treatment using Fixed-Dose Combination of Perindropril/Amlodipine
per: Evan Hindoro, et al.
Publicat: (2015-12-01)

Fixed dosed combinations in the treatment of hypertension
per: Gabriel Hancu, et al.
Publicat: (2020-03-01)

Bioequivalence study of fixed-dose combination Losartan + amlodipine + rosuvastatin Sanofi in comparison with coadministered fixed- dose combination Lozap® AM and monocomponent drug Crestor® in healthy subjects
per: A. L. Khokhlov, et al.
Publicat: (2022-05-01)

Assessment of treatment outcomes of daily fixed-dose combination therapy among drug-sensitive pulmonary tuberculosis patients: A prospective study from Bengaluru, India
per: M Sumana, et al.
Publicat: (2024-07-01)

From combined therapy to fixed-dose combinations
per: I. P. Kolos, et al.
Publicat: (2008-08-01)

A promising choice in hypertension treatment: Fixed-dose combinations
per: Xinhuan Wan, et al.
Publicat: (2014-02-01)

Fixed-dose versus separate drug combinations for antihypertensive treatment: literature review
per: José Luis Calleja Rivero
Publicat: (2016-09-01)

Fixed-dose combination associated with faster time to smear conversion compared to separate tablets of anti-tuberculosis drugs in patients with poorly controlled diabetes and pulmonary tuberculosis in Qatar
per: Mohammad H. Al-Shaer, et al.
Publicat: (2018-08-01)

Therapy compliance and fixed-dose combinations in arterial hypertension treatment. Focus on a fixed-dose combination of felodipine and metoprolol
per: S. A. Shalnova, et al.
Publicat: (2009-12-01)

The Roll-out of Child-friendly Fixed-dose Combination TB Formulations in High-TB-Burden Countries: A Case Study of STEP-TB
per: Lena Faust, et al.
Publicat: (2019-08-01)

Modern antihypertensive therapy: the effectiveness of a unique Russian fixed-dose combination of ramipril and indapamide
per: A. O. Konradi, et al.
Publicat: (2020-04-01)

Critical Analysis of Cardiovascular and Central Nervous System Fixed Dose Combinations Available in Indian Market
per: Krunal Prajapati, et al.
Publicat: (2016-12-01)

Fixed-dose combinations in the treatment of hypertension to increase adherence
per: T. E. Morozova, et al.
Publicat: (2020-12-01)

A cost-minimization analysis of combination therapy in hypertension: fixed-dose vs extemporary combinations
per: Marco Bellone, et al.
Publicat: (2013-12-01)

Pharmacokinetics and relative bioavailability of fixed-dose combination of clopidogrel and aspirin versus coadministration of individual formulations in healthy Korean men
per: Choi HK, et al.
Publicat: (2016-10-01)

Sitagliptin/metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy
per: Hayes J, et al.
Publicat: (2016-07-01)

Enhanced Stability and Compatibility of Montelukast and Levocetirizine in a Fixed-Dose Combination Monolayer Tablet
per: Tae Han Yun, et al.
Publicat: (2024-07-01)

The use of capillary electrophoresis in the simultaneous determination of fixed-dose combination drugs for cardiovascular diseases
per: Gabriel Hancu, et al.
Publicat: (2020-09-01)

Regulatory requirements for marketing fixed dose combinations
per: B G Jayasheel
Publicat: (2010-01-01)

Clinical use of a fixed-dose combination of telmisartan and indapamide in hypertension. Expert Council resolution
per: A. O. Konradi, et al.
Publicat: (2025-02-01)

Clinical Benefit of Fixed‐Dose Combination of Amlodipine and Potent Atorvastatin in Patients With Concomitant Hypertension and Hypercholesterolemia
per: Chia‐Pin Lin, et al.
Publicat: (2024-05-01)

The Adherence to Fixed-Dose Combination Antiretroviral Therapy and Viral Load in HIV Patients
per: Salma Auliannissa, et al.
Publicat: (2020-01-01)

LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review
per: Rogliani P, et al.
Publicat: (2018-10-01)

From Scylla to Charybdis: Fixed drug combinations for tuberculosis and increased ethambutol-induced optic neuropathy in India
per: Archana Bhargava, et al.
Publicat: (2022-01-01)

Comparative pharmacokinetics of a fixed-dose combination vs concomitant administration of telmisartan and S-amlodipine in healthy adult volunteers
per: Oh M, et al.
Publicat: (2017-12-01)

IMPACT OF THE FORM OF MEDICATION ON TREATMENT ADHERENCE IN RESPIRATORY TUBERCULOSIS PATIENTS
per: T. E. Tyulkova, et al.
Publicat: (2018-01-01)

Triple fixed-dose combination in the treatment of hypertension: the results of the Russian observational study TRICOLOR
per: Yu. A. Karpov, et al.
Publicat: (2020-11-01)

Pharmacokinetic comparison of a fixed-dose combination versus concomitant administration of amlodipine, olmesartan, and rosuvastatin in healthy adult subjects
per: Oh M, et al.
Publicat: (2019-04-01)

Desenvolvimento e validação de método analítico para determinação simultânea de lamivudina, zidovudina e nevirapina em comprimidos dose-fixa combinada por cromatografia líquida de alta eficiência Development and validation of an analytical method for simultaneous determination of fixed-dose combination tablets of lamivudine, zidovudine and nevirapine by hight performance liquid chromatography
per: Zênia Maria Maciel Lavra, et al.
Publicat: (2008-01-01)

Socio-Demographic Profile, Treatment Outcome & Factors Influencing Outcome among Tuberculosis Cases Treated On Daily Regimen: A Cross-Sectional Study at District Tuberculosis Centre, Uttarakannada
per: Girish HO, et al.
Publicat: (2019-12-01)

Glyceroniosomes for enhanced intestinal absorption of hydrochlorothiazide and lisinopril in their fixed dose combination
per: Aya R. Elbasuony, et al.
Publicat: (2024-10-01)

Pharmacokinetics of a Fixed-Dose Combination Product of Dapagliflozin and Linagliptin and Its Comparison with Co-Administration of Individual Tablets in Healthy Humans
per: Jin-Woo Park, et al.
Publicat: (2022-03-01)